Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy

February 23-26, 2025
JW Marriott Los Angeles L.A. Live
Los Angeles, California

sign up to request additional information

Scientific Committee Chair:

Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

This new major conference will encompass the very best of basic, translational, and clinical research in immunology, inflammation and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The cutting-edge AACR IO 2025 program will appeal to a wide audience of basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. A mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits will cover the spectrum of the IO field – including late-breaking clinical trials sessions highlighting new agents and IO combinations, and the results of practice-changing clinical trials.

Scientific Committee Vice Chairs:

Yvonne Y. Chen, University of California, Los Angeles, California
Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington
Alena Gros, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain
Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
Georgina V. Long, University of Sydney, Sydney, NSW, Australia
Crystal L. Mackall, Stanford Hospital, Stanford, California
Ira Mellman, Genentech, Inc., South San Francisco, California
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina
Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
Ton Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands

Scientific Committee: 

Rostyslav Bilyy, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine 
David Chang, Allogene Therapeutics, Inc., South San Francisco, California
Sandra Demaria, Weill Cornell Medicine, New York, New York
Kavita M. Dhodapkar, Emory University, Atlanta, Georgia
Charles G. Drake, Janssen Pharmaceuticals, Spring House, Pennsylvania
Lawrence Fong, University of California, San Francisco, California
William N. Haining, Arsenal Biosciences, South San Francisco, California 
Matthew D. Hellmann, AstraZeneca Oncology, New York, New York
Juan C. Jaen, Arcus Biosciences, Burlingame, California
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
Alexander Marson, University of California, San Francisco, California
Flavius Martin, Gilead Sciences, Foster City, California
Ignacio Melero, Clínica Universidad de Navarra, Pamplona, Spain 
Avery Posey, University of Pennsylvania, Philadelphia, Pennsylvania
Sergio Quezada, University College London (UCL) Cancer Institute, London, England 
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York
Emmett V. Schmidt, Merck Research Laboratories, Rahway, New Jersey 
Stefani Spranger, Koch Institute for Integrative Cancer Research at MIT, Boston, Massachusetts
Charles Swanton, The Francis Crick Institute, London, England  
Takemasa Tsjui, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Eliezer Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
Catherine Wu, Dana-Farber Cancer Institute, Brookline, Massachusetts

Clinical Trials and Late-Breaking Abstracts Committee: